Item 1.01 Entry into a Material Definitive Agreement.
Effective
The foregoing description of the agreement is not complete and is qualified in its entirety by reference to the full text of the agreement, a copy of which is filed herewith as Exhibit 10.1.
This report contains forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express our intentions,
beliefs, expectations, strategies, predictions or any other statements related
to our future activities, or future events or conditions. These statements are
based on current expectations, estimates and projections about our business
based, in part, on assumptions made by management. These statements are not
guarantees of future performances and involve risks, uncertainties and
assumptions that are difficult to predict. Therefore, actual outcomes and
results may differ materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors, including those risks
discussed in our Annual Report on Form 10-K and in other documents that we file
from time to time with the
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. Exhibit Number Description 10.1†* Exclusive Distribution and Supply Agreement, datedJanuary 26, 2023 , by and betweenSonoma Pharmaceuticals, Inc. and Daewoong Pharmaceutical Co., Ltd. 104 Cover Page Interactive Data File (formatted in inline XBRL in Exhibit 101). _________________ † Certain portions of the agreement have been omitted to preserve the confidentiality of such information. The Company will furnish copies of any such information to theSEC upon request. * Some exhibits or schedules to the agreement have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K.The Company will furnish copies of any such schedule or exhibit to theSEC upon request. 2
© Edgar Online, source